Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Hedge Fund and Insider Trading News: Carl Icahn, Adage Capital Management, Pierre Andurand, Simpson Manufacturing Co, Inc. (SSD), Evans & Sutherland (ESCC), William Lyon Homes (WLH), and More

SandRidge Says to Evaluate Buyout Offers, Including Icahn’s (Reuters)
(Reuters) – SandRidge Energy Inc (SD.N) yielded to demands from top shareholder Carl Icahn on Monday and said it would evaluate any buyout offers, including one promised last week by the hedge fund manager himself. One of the best known of the hedge fund world’s aggressive activist players who seek major changes in company strategies, Icahn has been railing against the Oklahoma-based shale oil driller’s management for months. The company has already made substantial changes in response, in February replacing both its chief executive and finance chief. Icahn, who holds a 13.5 percent stake, also convinced SandRidge to back out of a $746 million deal to acquire Bonanza Creek Energy (BCEI.N) last year.

Hedge Fund Adage Reaps Big Initial Gain on Health-Care Takeover (Bloomberg)
Adage Capital Management, a $30 billion hedge fund founded by two former money mangers from Harvard University’s endowment, reaped an initial gain of more than $100 million Monday after Swiss drugmaker Novartis AG agreed to acquire AveXis Inc. AveXis, which has a promising drug to treat a rare disease that afflicts infants, rose 80 percent to $208.05 a share at 9:32 am in New York trading. Novartis’ $8.7 billion offer represented an 88 percent premium to AveXis’ Friday closing price.

Insider Trading Wall Street Trader Panic

Luis Louro /

Oil Trader Andurand’s Hedge Fund Fell in First Quarter: HSBC (Reuters)
LONDON (Reuters) – Oil trader Pierre Andurand’s hedge fund lost 6.7 percent in the first quarter of 2018 after recouping some of the heavy losses suffered in February, data compiled by HSBC showed. Andurand Capital made gains of 3.6 percent in March after losing 14.5 percent in February, following returns of 5.2 percent in January, the data showed. A spokesman for Andurand Capital declined to comment. Many commodities-focused hedge funds lost out on trades in commodities and energy betting on higher prices in February, a separate report from industry tracker Eurekahedge showed.

Bank Notes: After Buying Stake in Navient, Hedge Fund Wants Board Seat (
Navient said it received a notice of a regulatory filing from Los Angeles-based hedge fund Canyon Capital Advisors that indicated it would like a board seat on the student loan servicer. Canyon has purchased about 7.8 percent of Navient ’s stock for what is estimated to be valued at more than $260 million, according to the Schedule 13D filing with the Securities and Exchange Commission. Companies are required to file 13D’s when purchasing more than 5 percent of another companies shares. Canyon, which has more than $20 billion in assets, said in its filing that it discussed a vacant seat on the Navient board and the financial performance of the company.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.